Pneumococcal Infections
130
6
8
107
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Published Results
52 trials with published results (40%)
Research Maturity
107 completed trials (82% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
2.3%
3 terminated out of 130 trials
97.3%
+10.7% vs benchmark
49%
64 trials in Phase 3/4
49%
52 of 107 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 107 completed trials
Clinical Trials (130)
Surveillance of Invasive Pneumococcal Infections in Adults (Excluding Meningitis)
RANDOMIZED CONTROLLED TRIAL OF TEXT MESSAGE TO INCREASE PNEUMOCOCCAL VACCINATION IN ADULTS IN CHILE.
A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns
Systematic Search for Primary Immunodeficiency in Adults With Infections
Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab
Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People
In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)
Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
Extension Safety and Immunogenicity Study of GPNV-001
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage